Knockdown of enhancer of rudimentary homolog inhibits proliferation and metastasis in ovarian cancer by regulating epithelial-mesenchymal transition - 14/03/20













pages | 9 |
Iconographies | 6 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | The ERH expression level is high in ovarian cancer. |
• | Patients with ovarian cancer with high expression of ERH have a poor prognosis. |
• | Knockdown of ERH could inhibit proliferation and promotes apoptosis in ovarian cancer cells. |
• | ERH can promote the metastasis of ovarian cancer by regulating EMT. |
• | ERH has potential as a molecular therapeutic target for ovarian cancer. |
Abstract |
Ovarian cancer (OC) is the deadliest gynecological malignancy. The pathogenesis of molecular in epithelial ovarian cancer (EOC), main histological type of OC, has not been completely defined. Enhancer of rudimentary homolog (ERH) had been reported to participate in transcriptional regulation, mRNA splicing, DNA repair and DNA synthesis by binding a variety of proteins. In this study, immunohistochemical staining revealed that the protein expression of ERH was associated with histological type, lymph node metastasis and pathological grade in EOC patients. To verify the association of ERH with the prognosis of OC, a GSE microarray dataset was downloaded from the Gene Expression Omnibus (GEO) database. Survival analysis suggested that ERH may be associated with poor prognosis of OC. In addition, shRNA was used to knockdown the protein and mRNA expression levels of ERH in the OC cell line SKOV3. Inhibition of ERH expression slowed proliferation, promoted apoptosis and inhibited metastasis and invasion by regulating epithelial-mesenchymal transition (EMT) in SKOV3 cells. These results indicate that ERH protein promotes the development of OC and provides an experimental basis for ERH as the potential target for ovarian cancer treatment.
Le texte complet de cet article est disponible en PDF.Keywords : Ovarian cancer, Proliferation, Nhancer of rudimentary homolog (ERH), Epithelial-mesenchymal transition (EMT)
Plan
Vol 125
Article 109974- mai 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?